OI Ljubljana
Sl

EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation

 

 

© 2019 - Institute of Oncology Ljubljana
Accessibility(CTRL+F2)
color contrast
text size
highlighting content
zoom in